medigraphic.com
ISSN 1561-2945 (Print)

2019, Number 2

<< Back Next >>

Revista Cubana de Cirugía 2019; 58 (2)

Epidemiological and clinical-therapeutic characterization of malignant neoplasm in the salivary glands

Rocha RP, Coca GRM, Fonseca PAJ

Language: Spanish
References: 18
Page: 1-14
PDF size: 393.30 Kb.


ABSTRACT

Introduction: Malignant neoplasms in the salivary glands are among the first ten locations of cancer incidence.
Objective: To describe the epidemiological, clinical and therapeutic behavior of malignant salivary gland tumors in patients older than 15 years in Sancti Spiritus Province between 2012 and 2105.
Methods: An observational, descriptive, cross-sectional study was carried out. The sample consisted of 39 patients older than 15 years, with salivary gland neoplasms and who attended the maxillofacial surgery service between January 1st, 2012 and December 31st, 2015.
Results: The male sex and the age range between 45-64 years predominated. The municipalities with the highest number of patients were Sancti Spiritus and Cabaiguán. 23.1% of workers are exposed to sunlight and chemicals. The most frequent clinical parameters were volume increase, discomfort, localized pain. The parotid gland was the most frequent anatomical onset site and the mucoepidermoid carcinoma was the most recurrent of the malignant neoplasms in the salivary glands. The two-year overall survival was 84.1%.
Conclusions: Malignant neoplasms of salivary glands constitute a health concern in the central region of the country. More than half of the cases are diagnosed in advanced stages due, in part, to the rural origin (hard-to-reach areas) of much of the sample. Survival rates are coincident with international parameters.


REFERENCES

  1. Gooden E, Witterick IJ, Hacker D, Rosen IB, Freeman JL. Parotid gland tumours in 255 consecutive patients: Mount Sinai Hospital's quality assurance review. J Otolaryngol. 2012;31(6):351-4.

  2. Pérez Abreu E, Orduñez García P, Cruz Leyva A. Tumores de glándulas salivales. Nuestra experiencia. Rev Cubana Estomatol. 2010;37(2):89-94.

  3. Boza-Mejías Y, Romero-Rodríguez J, Pérez-Abreus E, López-Fernández R, Duménico-Soler A, Barrios T. Tumores de las glándulas salivales mayores. Estudio de una serie de casos. Revista Finlay. 2012 [acceso: 05/01/2018];2(3). Disponible en: http://www.revfinlay.sld.cu/index.php/finlay/article/view/124

  4. Ferbeyre Binelfa L, Cruz González P, Fernández Mirabal A, Sánchez Acuña G, Medina Suárez M. Tumores de glándulas salivales: Experiencia en Cuba en comparación con otros países. Gaceta Mexicana de Oncología. 2009 sept-oct;5(5): 154-60.

  5. Auclair PL, Goode RK, Ellis GL. Mucoepidermoid carcinoma of intraoral salivary glands. Evaluation and application of grading criteria in 143 cases. Cancer. 2012;69(8):2021-30.

  6. Eveson JW, Cawson RA. Salivary gland tumours. A review of 2410 cases with particular reference to histological types, site, age and sex distribution. J Pathol. 2009;146(1):51-8.

  7. Boon E, van Boxtel W, Buter J, Baatenburg de Jong RJ, van Es RJJ, et al. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands. Head Neck. 2018 Mar;40(3):605-13

  8. Chen AA, Gheit T, Stellin M, Lupato V, Spinato G, Fuson R, et al. Oncogenic DNA viruses found in salivary gland tumors. Oral Oncol. 2017;75:106-10.

  9. De Felice F, de Vincentiis M, Valentini V, Musio D, Mezi S, Lo Mele L, et al. Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendations. Crit Rev Oncol Hematol. 2017;120:93-7.

  10. Soper MS, Iganej S, Thompson LD. Definitive treatment of androgen receptor-positive salivary duct carcinoma with androgen deprivation therapy and external beam radiotherapy. Head Neck. 2014;36(1):E4-7.

  11. Yamamoto N, Minami S, Fujii M. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy. Am J Otolaryngol. 2014;35(6):731-5.

  12. Seethala Raja R, Stenman Goran. Update from the 4th Edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland. Head and Neck Pathol. 2017;11:55-67.

  13. Park GC, Roh JL, Cho KJ, Jung YG, Lee HW, Kim TG, et al. Survival Outcome of Intermediate-Grade Salivary Gland Carcinoma. Oncology. 2018:94(2):125-32.

  14. Aro K, Tarkkanen J, Saat R, Saarilahti K, Makitie A, Atula T. Submandibular gland cancer: Specific features and treatment considerations. Head Neck. 2018;40(1):154-62.

  15. Guevara-Canales JO, Morales Vadillo R, Guzmán Arias G, Cava-Vergiú CE, Robello-Malatto JM, Guerra-Miller H, et al. Mucoepidermoid Carcinoma of the Salivary Glands: Survival and Prognostic Factors. J Maxillofac Oral Surg. 2017;16(4):431-7.

  16. Pommier A, Lerat J, Orsel S, Bessede JP, Aubry K. Cyto-histological correlation in the management of parotid gland tumors: A retrospective study of 160 cases. Bull Cancer. 2017;104(10):850-7.

  17. Maleki Z, Miller JA, Arab SE, Fadda G, Bo P, Wise O, et al. “Suspicious" salivary gland FNA: Risk of malignancy and interinstitutional variability. Cancer Cytopathol. 2018;126(2):94-100.

  18. Maleki Z, Miller JA, Arab SE, Fadda G, Bo P, Wise O, et al. A brief history of salivary gland surgery. Rev Col Bras Cir. 2017;44(4):403-12.




2020     |     www.medigraphic.com